Evidence map›Paper›PMID 20922428›Full record

ArticleParasitology research2011

Antileishmanial activity of imidothiocarbamates and imidoselenocarbamates.

David Moreno, Daniel Plano, Ylenia Baquedano, Antonio Jiménez-Ruiz, Juan Antonio Palop, Carmen Sanmartín

Abstract read
PubMed Publisher
In one paragraph

Article in Parasitology research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
5.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 46 citations in OpenAlex.

  1. Review
  2. Article
  3. The repertoire of iron superoxide dismutases fromJournal of enzyme inhibition and medicinal chemistry · 2024
    Article
  4. Novel Schiff bases of Vanillin: potent inhibitors of macrophage harboredJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2023
    Article
  5. Article
  6. New Phosphoramidates Containing Selenium as Leishmanicidal Agents.Antimicrobial agents and chemotherapy · 2021
    Article
  7. Article
  8. Prolyl Oligopeptidase FromFrontiers in microbiology · 2020
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

David MorenoDepartamento de Bioquímica y Biología Molecular, Universidad de Alcalá, Carretera Madrid-Barcelona Km 33,600, 28871 Alcalá de Henares, Madrid, Spain.
Daniel Plano
Ylenia Baquedano
Antonio Jiménez-Ruiz
Juan Antonio Palop
Carmen Sanmartín
Universidad de Navarra · ESUniversidad de Alcalá · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the present study, a family of 15 imidothio- and imidoselenocarbamates (1-15) analogs have been synthesized and screened for their in vitro antileishmanial potential against Leishmania infantum promastigotes. The six most active ones (2, 4, 7, 13, 14, and 15) were also tested in an axenic amastigote model. In order to establish their selectivity indexes (SI) the cytotoxic effect of each compound was also assayed against Jurkat and THP-1 cell lines. Compounds 2 and 4, both with a pyridine moiety, showed a moderate antileishmanial activity with an IC(50) value of 4.68 ± 0.46 and 3.03 ± 0.24 μM, respectively, in the amastigote model. The activity was compared with that of standard drugs, edelfosine (IC₅₀ = 0.82 ± 0.13 μM) and miltefosine (IC₅₀ = 2.84 ± 0.10 μM). Related to selectivity, the SI of both compounds are similar to those of the standard drugs when compared against the THP-1 cell line. Moreover, compound 4 was able to reduce the number of amastigote-infected THP-1 cells to 40% of that observed in untreated controls after a 96-h period of treatment. These derivatives thus represent two new leads for further studies aimed at establishing their mechanism of action.

Indexed as

Antiprotozoal AgentsCarbamatesCell LineCell SurvivalHumansImidesInhibitory Concentration 50Leishmania infantumParasitic Sensitivity TestsSeleniumTime FactorsAntiprotozoal AgentsCarbamatesImidesSelenium

Identifiers

PMID20922428
OpenAlexW1996640816

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.